New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

It works by blocking tissue factor pathway inhibitor (TFPI), a protein that limits blood clotting, thereby increasing thrombin production to help manage bleeding episodes in the presence of ...

The results of the Explorer7 trial showed that concizumab – an anti-tissue factor pathway inhibitor (TFPI) antibody – reduced the number of treated bleeds in patients by 86% when given as a ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...